Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia

• Published in: European journal of pharmacology Vol. 769; pp. 93 - 99
• Main Authors: Kałużna, Ewelina, Strauss, Ewa, Zając-Spychała, Olga, Gowin, Ewelina, Świątek-Kościelna, Bogna, Nowak, Jerzy, Fichna, Marta, Mańkowski, Przemysław, Januszkiewicz-Lewandowska, Danuta
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.12.2015
• Subjects: Acute lymphoblastic leukemia; Adolescent; Child; Child, Preschool; Female; Folate metabolism; Folic Acid - metabolism; Gene Frequency; Genotype; Humans; Male; Methotrexate - adverse effects; Methotrexate - therapeutic use; Methylenetetrahydrofolate Reductase (NADPH2) - genetics; Methylenetetrahydrofolate Reductase (NADPH2) - metabolism; MTHFR polymorphism; Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - enzymology; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics; Acute lymphoblastic leukemia; Folate metabolism; MTHFR polymorphism
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2015.10.058

Methotrexate (MTX) is commonly used agent in therapy of malignancies, including acute lymphoblastic leukemia (ALL). Based on the literature data it is known that MTX elimination and toxicity can be affected by polymorphisms in genes encoding enzymes involved in MTX metabolism. The aim of our study was to investigate the influence of C677T and A1298C polymorphisms in methylenetetrahydrofolate reductase (MTHFR) gene on MTX-induced toxicity during treatment of children with ALL. We also tried to answer the question whether simultaneous occurrence of these two polymorphisms has a clinical significance. MTHFR polymorphisms were assessed in 47 pediatric ALL patients, treated according to intensive chemotherapy for childhood ALL, ALL IC BFM 2009. Prolonged MTX elimination and higher incidence of toxicity were observed for patients with 677T-1298A haplotype. On the other hand, occurrence of 677C-1298A haplotype had protective effect on MTX clearance and toxicity, that was not observed in carriers of 677C-1298C haplotype. In patients with coexistence of studied variants 677CT/1298AC heterozygotes as well as in 677TT/1298AA homozygotes more frequently toxicity incidents were noted. The obtained results suggest that occurrence of 677T allele and coexistence of 677T and 1298C alleles may be associated with lower MTX clearance and elevated risk of adverse effects during MTX-treatment of pediatric ALL patients.